4 days ago
Jim Cramer openly shares his opinions about various stocks, and on September 3, 2026, during an episode of CNBC's Mad Money, he gave his two cents on Nuvation Bio (NUVB).
A caller asked about the surging biopharma name, and Cramer answered in five plain words: "This is a pure spec."
That is short for pure speculation, which implies a stock that trades on what a drug might do someday, not on the money the company is making right now.
His warning came as the stock climbed on real news, which is exactly what makes Nuvation such a tricky call for investors.
Cramer has hosted Mad Money since 2005 and ran a hedge fund for years before that, so when he flags a stock as too risky for most people, it carries weight.
#cramer #nuvation #pure #shares
A caller asked about the surging biopharma name, and Cramer answered in five plain words: "This is a pure spec."
That is short for pure speculation, which implies a stock that trades on what a drug might do someday, not on the money the company is making right now.
His warning came as the stock climbed on real news, which is exactly what makes Nuvation such a tricky call for investors.
Cramer has hosted Mad Money since 2005 and ran a hedge fund for years before that, so when he flags a stock as too risky for most people, it carries weight.
#cramer #nuvation #pure #shares
2 months ago
Nuvation Bio Inc (NYSE:NUVB) is one of billionaire David Abrams' top stock picks with upside potential. Nuvation Bio shares gained nearly 170% over the past year, and ******* ysts project a more than 150% upside for the stock over the next 12 months. Some 41 hedge funds are backing Nuvation Bio stock.
Copyright: dolgachov / 123RF Stock Photo
This comes as Nuvation Bio Inc (NYSE:NUVB) works to expand the market for its lung cancer drug. On June 29, Nuvation Bio said that the UK drug regulator had accepted the marketing application for its lung cancer drug and would review the request to decide whether to approve or reject it. The marketing application was submitted by Nuvation Bio's partner Eisai.
The drug, known as taletrectinib, targets advanced ROS1-positive non-small cell lung cancer. Nuvation Bio has already secured marketing approvals for the drug in the US, ******* an, and China. It is seeking the drug's approval in the UK and other international markets.
In the meantime, Nuvation Bio is shoring up its balance sheet. The company exited Q1 2026 with $533.7 million in ash, cash equivalents, and marketable securities and recently raised $287.5 million through a notes offering.
Copyright: dolgachov / 123RF Stock Photo
This comes as Nuvation Bio Inc (NYSE:NUVB) works to expand the market for its lung cancer drug. On June 29, Nuvation Bio said that the UK drug regulator had accepted the marketing application for its lung cancer drug and would review the request to decide whether to approve or reject it. The marketing application was submitted by Nuvation Bio's partner Eisai.
The drug, known as taletrectinib, targets advanced ROS1-positive non-small cell lung cancer. Nuvation Bio has already secured marketing approvals for the drug in the US, ******* an, and China. It is seeking the drug's approval in the UK and other international markets.
In the meantime, Nuvation Bio is shoring up its balance sheet. The company exited Q1 2026 with $533.7 million in ash, cash equivalents, and marketable securities and recently raised $287.5 million through a notes offering.
